Gastroprotective therapy in patients with atrial fibrillation receiving anticoagulant therapy: A review

Prevention of thromboembolic complications is the main goal in patients with atrial fibrillation. Anticoagulant therapy used as prophylaxis, and direct oral anticoagulants are preferred. However, this associated a risk bleeding, among which gastrointestinal bleeding takes leading place. Proton pump inhibitors now widely prophylaxis for upper bleedings, but when long-term, may be number adverse drug reactions, including an increased cardiovascular events. Long-term use these drugs suppress action antiplatelet drugs, disrupt function vascular endothelium, at same time cause hypomagnesemia, iron deficiency, vitamin D K deficiency. At time, monotherapy proton does not protect against from lower tract. Thus, effective gastro- enteroprotection, it necessary to prescribe that tract throughout its entire length. Such rebamipide, has complex protective effect on tract, protecting mucous membrane all levels (pre-, post-epithelial directly epithelial level), ensures restoration tight contacts epithelium intestinal tube It should noted current consensus documents experts problem decreasing bleedings during anticoagulant treatment recommend rebamipide duration therapy.